Haan, Germany

Karl Ziegelbauer


 

Average Co-Inventor Count = 7.7

ph-index = 3

Forward Citations = 41(Granted Patents)


Location History:

  • Wuppertal, DE (1997 - 1999)
  • Kyoto, JP (2004)
  • Haan, DE (2003 - 2021)

Company Filing History:


Years Active: 1997-2021

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Karl Ziegelbauer

Introduction

Karl Ziegelbauer is a notable inventor based in Haan, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for cancer and anti-inflammatory compounds. With a total of 11 patents, Ziegelbauer's work has had a profound impact on medical science.

Latest Patents

Among his latest patents is a groundbreaking invention that combines regorafenib and acetylsalicylic acid for treating cancer. This invention relates to pharmaceutical compositions and combinations that aim to treat, prevent, or manage hyperproliferative disorders, including cancer in humans and other mammals. Another notable patent involves pyridine derivatives, specifically pyrimidine compounds that exhibit excellent anti-inflammatory activity and other biological effects.

Career Highlights

Ziegelbauer has worked with prominent companies in the pharmaceutical industry, including Bayer Aktiengesellschaft and Bayer Pharma Aktiengesellschaft. His experience in these organizations has allowed him to develop innovative solutions that address critical health issues.

Collaborations

Throughout his career, Ziegelbauer has collaborated with esteemed colleagues such as Toshiki Murata and Masaomi Umeda. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Karl Ziegelbauer's contributions to the field of pharmaceuticals are noteworthy, with his innovative patents paving the way for new treatments in cancer and inflammation. His work continues to inspire advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…